Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C

Vittorio Laghi, Fabrizio Toccaceli, Silvia Rosati, Antonella Monini, Maria Grimaldi, Gianni Foglianti, Nadia Canova, Ernesto Palazzini

Research output: Contribution to journalArticle

Abstract

Background/Aims: This study was carried in order to investigate whether human leukocyte interferon-α administered for 12 months at two different dosages, improves long-term responses in chronic hepatitis C and to see whether pre-treatment γ-glutamyl transpeptidase values help to predict the clinical response to Interferon. Methodology: Forty-five patients were treated for 12 months with natural Interferon-α: 3 MU (group A: 31 cases); 6 MU (group B: 14 cases). Biochemical and virological responses were monitored during treatment and follow-up. Results: Alanine aminotransferase was normalized in 58.1% (Group A) and 54.5% (Group B) of patients by the end of the treatment. Due to side effects 3 patients had to discontinue treatment. During follow-up, remission was maintained in 30.8% and 45.4% of patients respectively (p = 0.046). After 12 months of therapy, respectively 46.7% and 45.4% of patients with complete biochemical response, cleared virus from serum, as did, among long-term responders, 3/8 and 3/4 evaluated patients. Independently of dosage, a complete response was found more often in patients with normal pre-treatment γ-glutamyl transpeptidase than in those with pre-treatment abnormal values. Conclusions: High dosage of IFNα was associated with a significantly greater rate of sustained biochemical response and with a better chance of viremia becoming negative. Pre-treatment γ-glutamyl transpeptidase was able to predict the outcome of the treatment.

Original languageEnglish
Pages (from-to)1182-1186
Number of pages5
JournalHepato-Gastroenterology
Volume44
Issue number16
Publication statusPublished - 1997

Fingerprint

Chronic Hepatitis C
Interferon-alpha
gamma-Glutamyltransferase
Therapeutics
Interferons
Viremia
Alanine Transaminase
Viruses
Serum

Keywords

  • Gamma-glutamyltranspeptidase
  • Hepatitis C viruses
  • Hepatitis chronic active
  • Natural interferon alpha

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Laghi, V., Toccaceli, F., Rosati, S., Monini, A., Grimaldi, M., Foglianti, G., ... Palazzini, E. (1997). Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. Hepato-Gastroenterology, 44(16), 1182-1186.

Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. / Laghi, Vittorio; Toccaceli, Fabrizio; Rosati, Silvia; Monini, Antonella; Grimaldi, Maria; Foglianti, Gianni; Canova, Nadia; Palazzini, Ernesto.

In: Hepato-Gastroenterology, Vol. 44, No. 16, 1997, p. 1182-1186.

Research output: Contribution to journalArticle

Laghi, V, Toccaceli, F, Rosati, S, Monini, A, Grimaldi, M, Foglianti, G, Canova, N & Palazzini, E 1997, 'Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C', Hepato-Gastroenterology, vol. 44, no. 16, pp. 1182-1186.
Laghi, Vittorio ; Toccaceli, Fabrizio ; Rosati, Silvia ; Monini, Antonella ; Grimaldi, Maria ; Foglianti, Gianni ; Canova, Nadia ; Palazzini, Ernesto. / Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. In: Hepato-Gastroenterology. 1997 ; Vol. 44, No. 16. pp. 1182-1186.
@article{b2c06473094a4730a5a656a76bb844b9,
title = "Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C",
abstract = "Background/Aims: This study was carried in order to investigate whether human leukocyte interferon-α administered for 12 months at two different dosages, improves long-term responses in chronic hepatitis C and to see whether pre-treatment γ-glutamyl transpeptidase values help to predict the clinical response to Interferon. Methodology: Forty-five patients were treated for 12 months with natural Interferon-α: 3 MU (group A: 31 cases); 6 MU (group B: 14 cases). Biochemical and virological responses were monitored during treatment and follow-up. Results: Alanine aminotransferase was normalized in 58.1{\%} (Group A) and 54.5{\%} (Group B) of patients by the end of the treatment. Due to side effects 3 patients had to discontinue treatment. During follow-up, remission was maintained in 30.8{\%} and 45.4{\%} of patients respectively (p = 0.046). After 12 months of therapy, respectively 46.7{\%} and 45.4{\%} of patients with complete biochemical response, cleared virus from serum, as did, among long-term responders, 3/8 and 3/4 evaluated patients. Independently of dosage, a complete response was found more often in patients with normal pre-treatment γ-glutamyl transpeptidase than in those with pre-treatment abnormal values. Conclusions: High dosage of IFNα was associated with a significantly greater rate of sustained biochemical response and with a better chance of viremia becoming negative. Pre-treatment γ-glutamyl transpeptidase was able to predict the outcome of the treatment.",
keywords = "Gamma-glutamyltranspeptidase, Hepatitis C viruses, Hepatitis chronic active, Natural interferon alpha",
author = "Vittorio Laghi and Fabrizio Toccaceli and Silvia Rosati and Antonella Monini and Maria Grimaldi and Gianni Foglianti and Nadia Canova and Ernesto Palazzini",
year = "1997",
language = "English",
volume = "44",
pages = "1182--1186",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "16",

}

TY - JOUR

T1 - Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C

AU - Laghi, Vittorio

AU - Toccaceli, Fabrizio

AU - Rosati, Silvia

AU - Monini, Antonella

AU - Grimaldi, Maria

AU - Foglianti, Gianni

AU - Canova, Nadia

AU - Palazzini, Ernesto

PY - 1997

Y1 - 1997

N2 - Background/Aims: This study was carried in order to investigate whether human leukocyte interferon-α administered for 12 months at two different dosages, improves long-term responses in chronic hepatitis C and to see whether pre-treatment γ-glutamyl transpeptidase values help to predict the clinical response to Interferon. Methodology: Forty-five patients were treated for 12 months with natural Interferon-α: 3 MU (group A: 31 cases); 6 MU (group B: 14 cases). Biochemical and virological responses were monitored during treatment and follow-up. Results: Alanine aminotransferase was normalized in 58.1% (Group A) and 54.5% (Group B) of patients by the end of the treatment. Due to side effects 3 patients had to discontinue treatment. During follow-up, remission was maintained in 30.8% and 45.4% of patients respectively (p = 0.046). After 12 months of therapy, respectively 46.7% and 45.4% of patients with complete biochemical response, cleared virus from serum, as did, among long-term responders, 3/8 and 3/4 evaluated patients. Independently of dosage, a complete response was found more often in patients with normal pre-treatment γ-glutamyl transpeptidase than in those with pre-treatment abnormal values. Conclusions: High dosage of IFNα was associated with a significantly greater rate of sustained biochemical response and with a better chance of viremia becoming negative. Pre-treatment γ-glutamyl transpeptidase was able to predict the outcome of the treatment.

AB - Background/Aims: This study was carried in order to investigate whether human leukocyte interferon-α administered for 12 months at two different dosages, improves long-term responses in chronic hepatitis C and to see whether pre-treatment γ-glutamyl transpeptidase values help to predict the clinical response to Interferon. Methodology: Forty-five patients were treated for 12 months with natural Interferon-α: 3 MU (group A: 31 cases); 6 MU (group B: 14 cases). Biochemical and virological responses were monitored during treatment and follow-up. Results: Alanine aminotransferase was normalized in 58.1% (Group A) and 54.5% (Group B) of patients by the end of the treatment. Due to side effects 3 patients had to discontinue treatment. During follow-up, remission was maintained in 30.8% and 45.4% of patients respectively (p = 0.046). After 12 months of therapy, respectively 46.7% and 45.4% of patients with complete biochemical response, cleared virus from serum, as did, among long-term responders, 3/8 and 3/4 evaluated patients. Independently of dosage, a complete response was found more often in patients with normal pre-treatment γ-glutamyl transpeptidase than in those with pre-treatment abnormal values. Conclusions: High dosage of IFNα was associated with a significantly greater rate of sustained biochemical response and with a better chance of viremia becoming negative. Pre-treatment γ-glutamyl transpeptidase was able to predict the outcome of the treatment.

KW - Gamma-glutamyltranspeptidase

KW - Hepatitis C viruses

KW - Hepatitis chronic active

KW - Natural interferon alpha

UR - http://www.scopus.com/inward/record.url?scp=0030803372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030803372&partnerID=8YFLogxK

M3 - Article

C2 - 9261621

AN - SCOPUS:0030803372

VL - 44

SP - 1182

EP - 1186

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 16

ER -